Ormeloxifene Versus Norethisterone for Anovulatory Abnormal Uterine Bleeding: An India-Based Systematic Review and Meta-Analysis
Saranya Devi, Hemavathy V, Reenaa Mohan, Arularasan J, Preethi Tamilarasan, Suja Xaviar, Saravanan Vaithiyalingam · 2025
Read Ormeloxifene Versus Norethisterone for Anovulatory Abnormal Uterine Bleeding: An India-Based Systematic Review and Meta-Analysis by Saranya Devi, Hemavathy V, Reenaa Mohan, Arularasan J, Preethi Tamilarasan, Suja Xaviar, Saravanan Vaithiyalingam (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12831494.txt.
Description
Saranya Devi and co-authors compare two drugs for abnormal uterine bleeding in a 2025 review. The bleeding here stems from failed ovulation and hits women in reproductive and menopausal years. Norethisterone, a synthetic progestogen, is the long-used standard for medical control.
Ormeloxifene, which tunes estrogen receptors, has emerged as a rival option. The team searched major databases and pooled Indian trials under standard review rules. The study was also registered in advance, a mark of careful review practice. Efficacy and safety were weighed head to head across the trials. Women who want hormone care without surgery need exactly this kind of pooled verdict.
Catalog record
| CREATOR | Saranya Devi, Hemavathy V, Reenaa Mohan, Arularasan J, Preethi Tamilarasan, Suja Xaviar, Saravanan Vaithiyalingam |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |